TNSN08235A1 - Formulations of quinolinones - Google Patents

Formulations of quinolinones

Info

Publication number
TNSN08235A1
TNSN08235A1 TNP2008000235A TNSN08235A TNSN08235A1 TN SN08235 A1 TNSN08235 A1 TN SN08235A1 TN P2008000235 A TNP2008000235 A TN P2008000235A TN SN08235 A TNSN08235 A TN SN08235A TN SN08235 A1 TNSN08235 A1 TN SN08235A1
Authority
TN
Tunisia
Prior art keywords
compound
quinolinones
formulations
tautomer
salt
Prior art date
Application number
TNP2008000235A
Inventor
Joyce Chou
Augustus Okhamafe
Patricia Frech
Rampurma Gullapalli
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/045711 external-priority patent/WO2007064719A2/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TNSN08235A1 publication Critical patent/TNSN08235A1/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02W—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO WASTEWATER TREATMENT OR WASTE MANAGEMENT
    • Y02W90/00—Enabling technologies or technologies with a potential or indirect contribution to greenhouse gas [GHG] emissions mitigation
    • Y02W90/10—Bio-packaging, e.g. packing containers made from renewable resources or bio-plastics

Abstract

A pharmaceutical formulation, comprising: a compound of formula (I), a tautomer of the compound, a salt of the compound, a salt of the tautomer, or a mixture thereof and at least one ingredient selected from the group consisting of (i) cellulose; (ii) silicon dioxide; (iii) magnesium stearate; and (iv) an ingredient selected from crospovidone, starch, or lactose.
TNP2008000235A 2005-11-29 2008-05-28 Formulations of quinolinones TNSN08235A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74057705P 2005-11-29 2005-11-29
PCT/US2006/045711 WO2007064719A2 (en) 2005-11-29 2006-11-29 Formulations of quinolinones

Publications (1)

Publication Number Publication Date
TNSN08235A1 true TNSN08235A1 (en) 2009-10-30

Family

ID=40107305

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2008000235A TNSN08235A1 (en) 2005-11-29 2008-05-28 Formulations of quinolinones

Country Status (3)

Country Link
CN (1) CN101316593B (en)
TN (1) TNSN08235A1 (en)
ZA (1) ZA200803213B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2393949T3 (en) * 2008-07-03 2013-01-02 Novartis Ag Granulation process in molten state
AR081776A1 (en) * 2010-06-30 2012-10-17 Novartis Ag PHARMACEUTICAL COMPOSITIONS INCLUDING 4-AMINO-5-FLUORO-3- LACTATE MONOHIDRATE [6- (4-METHYL-PIPERAZIN-1-IL) -1H-BENCIMIDAZOL-2-IL] -1H-QUINOLIN-2-ONA, PROCESS FOR THE COMPOSITION PRODUCTION

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1565187A4 (en) * 2002-11-13 2010-02-17 Novartis Vaccines & Diagnostic Methods of treating cancer and related methods
BRPI0416143A (en) * 2003-11-07 2007-01-02 Chiron Corp pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties

Also Published As

Publication number Publication date
CN101316593B (en) 2012-05-02
CN101316593A (en) 2008-12-03
ZA200803213B (en) 2009-02-25

Similar Documents

Publication Publication Date Title
TW200730176A (en) Formulations of quinolinones
WO2007087548A3 (en) Chemical compounds
WO2006025070A3 (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
WO2006096444A3 (en) Chemical compounds
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
MXPA05009985A (en) Cannabinoid receptor ligands.
MX2009008540A (en) Pyrimidine substituted macrocyclic hcv inhibitors.
WO2004074244A3 (en) Pyrimidine compounds
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
MXPA03010207A (en) Novel 4-anilinoquinoline-3-carboxamides.
SE0400284D0 (en) Novel compounds
RS20090036A (en) Pyrazole derivatives as cytochrom p450 inhibitors
EP1714961A4 (en) Indazole compound and pharmaceutical use thereof
NO20081844L (en) Therapeutic compounds
WO2003082205A3 (en) Compounds and methods
WO2007065595A3 (en) Xanthine derivatives, processes for preparing them and their uses
HK1097474A1 (en) Carbostyril derivatives for accelerating salivation
MY186650A (en) Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives
NO20080033L (en) Quinoline derivatives as NK3 antagonists
WO2007014839A3 (en) Cathepsin k inhibitors
WO2006110173A3 (en) Novel compounds
CA2437785A1 (en) Hiv inhibiting pyrazinone derivatives
WO2008004100A3 (en) Therapeutic compounds
WO2005118558A3 (en) Pyrimidine compounds and use thereof
GB0308201D0 (en) Novel compounds